Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT05550298 Recruiting - Clinical trials for Respiratory Viral Infection

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Start date: December 13, 2022
Phase:
Study type: Observational

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: - To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. - To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors .

NCT ID: NCT05549622 Recruiting - Sarcopenia Clinical Trials

Impact of Diet on the Gut-Muscle Axis in Older Adults

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Muscle health declines during aging. One factor that may impact muscle health is the community of bacteria that live in our intestines, but studies aimed at improving muscle health by targeting the gut in older adults are sparse. The primary goal of this study is to use a diet that is enriched in soluble fiber, which is exclusively utilized by gut bacteria to make substances that can impact muscle health, to improve muscle-related measures in older adults.

NCT ID: NCT05549115 Recruiting - Clinical trials for Helicobacter Pylori Infection

Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection

Start date: September 20, 2022
Phase: N/A
Study type: Interventional

The main objective of this trial is to assess whether a sequential therapy strategy based on molecular antibiotic susceptibility testing (including clarithromycin and fluoroquinolone) for H. pylori infection will improve the eradication rate compared to an empirical therapy.

NCT ID: NCT05547646 Completed - Critical Care Clinical Trials

The Prevalence of Healthcare-associated Infection in Medical Intensive Care Units in Tunisia

NOSOREA2
Start date: September 27, 2022
Phase:
Study type: Observational

We aimed to determine the prevalence of HAI in medical Tunisian ICUs. Secondary endpoints were to identify the predominant infecting microorganisms and evaluate independent risk factors of HAIs.

NCT ID: NCT05547373 Recruiting - Clinical trials for Hospital-acquired Infections

Infection Prevention and Control Intervention to Reduce Hospital-acquired Infections

IPC-HAI
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Hospital-acquired infections (HAIs) are significant public health issues, especially in low- and middle-income countries (LMICs). Hand hygiene and low-level disinfection of equipment (LLDE) practices among healthcare workers (HCWs) are essential to reduce HAIs. Various effective infection prevention and control (IPC) interventions to reduce HAI incidence have been developed. However, which interventions work effectively in LMICs has not been identified. The investigators aim to develop, pilot, and assess the feasibility and acceptability of an IPC intervention in Cambodia and the Lao People's Democratic Republic (PDR).

NCT ID: NCT05545514 Recruiting - Clinical trials for Urinary Tract Infection Chronic

Individualized Homeopathy to Reduce the Use of Antibiotics in Women With Recurrent Uncomplicated Urinary Tract Infections

iHOM
Start date: March 15, 2023
Phase: Phase 4
Study type: Interventional

The aim of the study is to determine the efficacy of individualised homeopathic drug treatment (potency C200 and C1000) compared to placebo in females (age 18<65) with recurrent urinary tract infections, per definition ≥ 2 UTI in 6 months and/ or ≥ 3 UTI in 9 months.

NCT ID: NCT05545137 Completed - Clinical trials for Uncomplicated Urinary Tract Infection

Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection

Start date: September 29, 2022
Phase: Phase 3
Study type: Interventional

the purpose of this study is to evaluate the efficacy and safety of pivmecillinam hydrochloride tablets in the treatment of uncomplicated urinary tract infection in China

NCT ID: NCT05544916 Completed - Influenza Clinical Trials

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Start date: August 5, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of the study was to evaluate the effectiveness of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other acute respiratory viral infections (ARIs). An additional purpose of the study was to evaluate the safety of XC221, tablets, at a dose of 200 mg/day compared to placebo in patients with uncomplicated influenza or other ARIs.

NCT ID: NCT05544682 Recruiting - Clinical trials for Multidrug Resistant Bacterial Infection

Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

CefiNoFer
Start date: September 1, 2022
Phase:
Study type: Observational

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli. The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)

NCT ID: NCT05543226 Not yet recruiting - Infections Clinical Trials

The Effect of PHGG-rich Enteral Nutrition to on the Infection in Liver Transplant Recipients: A Prospective, Double-blind, Randomized Controlled Study

Start date: October 1, 2022
Phase: Phase 4
Study type: Interventional

To known the effect of PHGG-rich enteral nutrition to on the infection in liver transplant recipients